Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.

View in: PubMed

subject areas

Antineoplastic Agents, Immunological
Cost-Benefit Analysis
Head and Neck Neoplasms
Humans
Models, Economic
Neoplasm Recurrence, Local
Quality-Adjusted Life Years
Survival Analysis
United States

authors with profiles

Ezra Cohen